GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals
MWN-AI** Summary
GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company, has announced significant progress in its Phase 1 trial for GTB-3650, a second-generation TriKE designed for treating relapsed or refractory (r/r) CD33 expressing hematologic malignancies. The company confirmed the successful completion of dosing in Cohort 1, allowing the trial to advance into Cohort 2 due to the absence of safety or tolerability issues. The first patient in Cohort 2 has begun the initial dosing cycle.
Initial results from Cohort 1 have been promising, with early signals of immune activation observed. Two patients showed increased immunologic activity, indicating that GTB-3650 may effectively activate and expand endogenous natural killer (NK) cells, pivotal in the body’s defense against cancer. The trial aims to evaluate GTB-3650’s safety, pharmacokinetics, pharmacodynamics, in vivo NK cell expansion, and clinical efficacy across seven cohorts, involving approximately 14 patients. Dosing will occur in two-week intervals, with treatment cycles based on clinical benefit over a four-month window.
Looking ahead, GT Biopharma plans to release more comprehensive results later in 2025 after completing additional dose cohorts. Stakeholders eagerly await these findings, as they may significantly influence the therapeutic landscape for hematologic malignancies. GT Biopharma’s proprietary TriKE platform harnesses the body’s immune system, aiming to enhance NK cell activity against tumors.
For ongoing updates, interested parties are encouraged to monitor clinicaltrials.gov for detailed trial information, under identifier NCT06594445. With its innovative approach to cancer treatment, GT Biopharma is positioned as a key player in the evolving field of immuno-oncology.
MWN-AI** Analysis
GT Biopharma, Inc. (NASDAQ: GTBP) has recently made significant strides with its Phase 1 trial of GTB-3650, a promising treatment for relapsed or refractory CD33 expressing hematologic malignancies. The transition from Cohort 1 to Cohort 2, following a favorable safety review, points to a stable foundational platform for the drug, evoking optimism amongst investors regarding its therapeutic potential and market position.
The successful completion of Cohort 1, characterized by the lack of safety and tolerability issues, sets a positive tone as the company conducts further research. Importantly, the evidence of early immune activation signals in Cohort 1 patients suggests that GTB-3650 can stimulate the body’s natural killer cells, enhancing the immune response against cancer. This is a crucial outcome for investors as it indicates the possibility of meaningful clinical benefits in future cohorts.
As GT Biopharma plans to release detailed results later in 2025, investors should keep an eye on the ongoing trials and any interim reports. The company's strategy to assess pharmacokinetics, pharmacodynamics, safety, and clinical activity will provide a comprehensive understanding of GTB-3650’s efficacy and market potential.
The market for immuno-oncology therapies is expanding rapidly, and if GTB-3650 demonstrates robust therapeutic outcomes, it could capture a significant share of this market. Given GT Biopharma’s exclusive license with the University of Minnesota for the TriKE technology, the potential for commercialization adds another layer of value.
While the stock remains susceptible to the volatility often associated with clinical trial outcomes, the encouraging early signals from GTB-3650 might be worthy of close monitoring and could present a compelling buy opportunity for investors interested in the biopharmaceutical sector. As always, potential investors should carefully consider the inherent risks and conduct thorough due diligence before making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2.
The company plans on releasing more detailed results from Phase 1 later in 2025 following completion of additional dose cohorts.
SAN FRANCISCO, CALIFORNIA, May 19, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE ® natural killer (NK) cell engager platform, today announced successful completion of dosing in Cohort 1 and subsequent initiation of dosing in Cohort 2 of its Phase 1 dose escalation trial evaluating GTB-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic malignancies.
GT Biopharma’s second-generation TriKE, GTB-3650, is currently being evaluated in a Phase 1 dose escalation trial for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic malignancies. Cohort 1 has been successfully completed with patients having undergone the first and second dosing cycles. Following the formal safety review, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2, with the first patient now having been treated with the first dose cycle.
Based on multiple assays of various blood biomarkers, both patients in Cohort 1 have shown early evidence of increased immunologic activity, supporting GTB-3650’s ability to activate endogenous NK cells and induce NK cell expansion. The company plans on releasing more detailed results later in 2025 following enrollment and completion of additional dose cohorts.
The trial plans to evaluate GTB-3650 in up to approximately 14 patients (seven cohorts) and GTB-3650 will be dosed in two-week blocks, two weeks on and two weeks off, for up to four months based on clinical benefit. The trial will assess safety, pharmacokinetics, pharmacodynamics, in vivo expansion of endogenous patient NK cells and clinical activity. More details can be found on clinicaltrials.gov with the identifier: NCT06594445 .
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE ® NK cell engager platform. Our TriKE ® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE ® technology. For more information, please visit gtbiopharma.com .
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.
TriKE ® is a registered trademark owned by GT Biopharma, Inc.
Investor Relations Contact:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577
FAQ**
What specific immunologic activity was observed in the early results from Cohort 1 of the GT Biopharma Inc. GTBP trial, and how might this influence the expected outcomes in Cohort 2?
Could you elaborate on the anticipated timeline for releasing detailed results from the Phase 1 trial of GTB-3650 by GT Biopharma Inc. GTBP later in 2025?
How does GT Biopharma Inc. GTBP plan to analyze the pharmacokinetics and pharmacodynamics of GTB-3650 during the trial, and what are the key metrics for success?
What potential risks and uncertainties should investors consider regarding the ongoing trial of GTB-3650 being conducted by GT Biopharma Inc. GTBP, especially with the focus on hematologic malignancies?
**MWN-AI FAQ is based on asking OpenAI questions about GT Biopharma Inc. (NASDAQ: GTBP).
NASDAQ: GTBP
GTBP Trading
-7.18% G/L:
$0.4084 Last:
1,935,580 Volume:
$0.4508 Open:
